Genistein for use in inhibiting osteroclasts

Overview

Information

Number
5506211
Application
08/241040
Filing date
05/09/1994
Issue date
04/09/1996
Inventor(s)
Stephen Barnes, Harry C. Blair
US Classification
424/439; 424/441; 514/25; 514/27; 514/456; 514/457
View at USPTO

Citations

Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. (2)
Yamanouchi Pharmaceutical Co. (2)
Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt. (1)
CHINOIN PHARMACEUTICAL AND CHEMICAL AND CO. (1)
Chinoin Pharmaceutical and Chemical Works (1)
Takeda Chemical Industries, (1)
ACDS Technologies, (1)

Abstract

Abstract

Disclosed are methods and compositions for use in inhibiting osteoclast activity and, particularly, the osteoclast acid secretion that leads to bone-degradation. It is shown that the isoflavone genistein inhibits the acid secretion of osteoclasts and reduces bone resorption. The present invention thus provides advantageous methods for use in inhibiting osteoclast activity, as may be employed to reduce bone loss, for example, in patients with osteoporosis, metastatic bone cancers and renal failure.

Assignees with Similar Patents

Eli lilly and (16)
smithkline beecham (6)
Board of Regents, the University of Texas System (5)
Bristol-Myers Squibb (5)
Merck & co. (5)

Referenced by

Archer-Daniels-Midland (18)
Novogen Research Pty. (9)
Energetics (3)
Abbott Laboratories (3)
NA (2)
Cargill (2)
Novogen (2)
Takeda (2)
DSM IP Assets B.V. (1)
lycored bio (1)
YAMAGUCHI, MASAYOSHI (1)
New York University Medical Center (1)
Regents of the University of California, The (1)
National Agriculture and Food Research Organization (1)
CAGILL (1)
Institut National de la Recherche Agronomique (1)
purina animal nutrition (1)
upfield us (1)
MARSHALL EDWARDS, INC. (1)
President And Fellows Of Harvard College (1)
MEIJI CO., LTD. (1)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF, UNITED STATES OF AMERICA, THE (1)
Wake Forest University (1)
Universitat Bern (1)

Tech Analysis

Class Subclass Type Reference Factor Citation Factor Strength Grant time Early grant (%)
424 439 Emerging Average Seminal Medium High Average 29.9
424 441 Emerging Novel Seminal High Average 38.4
514 25 Emerging Average Seminal Medium Average 26.0
514 27 Stable Average Seminal Medium Average 26.9
514 456 Emerging Average Seminal Medium Average 39.0
514 457 Stable Average Seminal Medium Average 36.5